Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial

Most patients with follicular lymphoma (FL) experience multiple relapses necessitating subsequent lines of therapy. Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor approved for the treatment of several B-cell malignancies, showed promising activity in FL in a phase 1 study. We report the results...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Bartlett, Nancy L., Costello, Brian A., LaPlant, Betsy R., Ansell, Stephen M., Kuruvilla, John G., Reeder, Craig B., Thye, Lim S., Anderson, Daniel M., Krysiak, Kilannin, Ramirez, Cody, Qi, Jing, Siegel, Barry A., Griffith, Malachi, Griffith, Obi L., Gomez, Felicia, Fehniger, Todd A.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2018
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5757691/
https://ncbi.nlm.nih.gov/pubmed/29074501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-09-804641
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky